PL372395A1 - Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence - Google Patents

Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence

Info

Publication number
PL372395A1
PL372395A1 PL03372395A PL37239503A PL372395A1 PL 372395 A1 PL372395 A1 PL 372395A1 PL 03372395 A PL03372395 A PL 03372395A PL 37239503 A PL37239503 A PL 37239503A PL 372395 A1 PL372395 A1 PL 372395A1
Authority
PL
Poland
Prior art keywords
incontinence
treatment
cyclooxygenase inhibitors
antimuscarinic agents
antimuscarinic
Prior art date
Application number
PL03372395A
Other languages
English (en)
Polish (pl)
Inventor
Ebrahim Versi
Original Assignee
Pharmacia Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corporation filed Critical Pharmacia Corporation
Publication of PL372395A1 publication Critical patent/PL372395A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL03372395A 2002-02-19 2003-02-14 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence PL372395A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35788802P 2002-02-19 2002-02-19

Publications (1)

Publication Number Publication Date
PL372395A1 true PL372395A1 (en) 2005-07-25

Family

ID=27757670

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372395A PL372395A1 (en) 2002-02-19 2003-02-14 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence

Country Status (12)

Country Link
US (1) US20030191172A1 (enExample)
EP (1) EP1476146A1 (enExample)
JP (1) JP2005526040A (enExample)
KR (1) KR20050005410A (enExample)
CN (1) CN1633283A (enExample)
AU (1) AU2003211078A1 (enExample)
BR (1) BR0307772A (enExample)
CA (1) CA2475374A1 (enExample)
MX (1) MXPA04008037A (enExample)
PL (1) PL372395A1 (enExample)
WO (1) WO2003070233A1 (enExample)
ZA (1) ZA200406148B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
EP1652523A4 (en) * 2003-08-04 2008-11-19 Kyorin Seiyaku Kk TRANSDERMALES ABSORPTION PREPARATION
CZ23088U1 (cs) * 2004-03-25 2011-12-19 Astellas Pharma Inc. Kompozice pevného farmaceutického prípravku solifenacinu nebo jeho soli
JP4895819B2 (ja) * 2004-10-29 2012-03-14 大鵬薬品工業株式会社 プロピベリン含有経口粉粒状製剤及びその製造法
WO2006082888A1 (ja) * 2005-02-03 2006-08-10 Kyorin Pharmaceutical Co., Ltd. 経皮吸収型製剤
WO2006090759A1 (ja) * 2005-02-25 2006-08-31 Astellas Pharma Inc. ソリフェナシン含有医薬
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
HRP20110634T1 (hr) * 2006-12-22 2011-10-31 Recordati Ireland Limited KOMBINIRANA TERAPIJA LIGANADA α<SUB>2</SUB>δ I NSAID ZA POREMEĆAJE DONJEG URINARNOG TRAKTA
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US8236857B2 (en) 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236856B2 (en) 2010-07-08 2012-08-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US10010514B2 (en) 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20120237574A1 (en) * 2010-07-08 2012-09-20 Wellesley Pharmaceuticals, Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10105330B2 (en) 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
EP2612660B1 (en) * 2012-01-04 2020-03-04 Wellesley Pharmaceuticals, LLC Extended-release formulation for reducing the frequency of urination and method of use thereof
TWI587879B (zh) * 2012-01-04 2017-06-21 魏斯理製藥公司 用於減少排尿頻率的延長釋放製劑及其使用方法
WO2013103389A1 (en) * 2012-01-04 2013-07-11 Wellesley Pharmaceuticals, Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
EP2612662B1 (en) * 2012-01-04 2020-03-04 Wellesley Pharmaceuticals, LLC Delayed-release formulation for reducing the frequency of urination and method of use thereof
CN103191429A (zh) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 用于缓解尿频的延长释放制剂及其使用方法
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
CN103191430A (zh) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 用于缓解尿频的缓释制剂及其使用方法
MX2014008283A (es) * 2012-01-04 2015-03-03 Wellesley Pharmaceutical Llc Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
EP2612663A1 (en) * 2012-01-04 2013-07-10 Wellesley Pharmaceuticals, LLC Extended-release formulation for reducing the frequency of urination and method of use thereof
CN107157991A (zh) * 2012-03-19 2017-09-15 韦尔斯利医药有限公司 用于缓解尿频的延长释放制剂及其使用方法
WO2014018223A1 (en) * 2012-07-27 2014-01-30 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
CN106714805A (zh) * 2014-06-06 2017-05-24 韦尔斯利医药有限公司 降低排尿频率的药物制剂及其使用方法
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
JP7195067B2 (ja) * 2018-06-20 2022-12-23 花王株式会社 ロズマリン酸誘導体又はその塩
JP2020033272A (ja) * 2018-08-27 2020-03-05 花王株式会社 過活動膀胱の予防又は改善剤
JP7223477B2 (ja) * 2018-10-10 2023-02-16 花王株式会社 Ｔｒｐｖ４活性抑制剤
CN110279863B (zh) * 2019-07-29 2022-02-22 牡丹江医学院 用于治疗泌尿疾病的药物组合物及其制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
IT1288123B1 (it) * 1996-09-04 1998-09-10 Nicox Sa Uso di nitroderivati per l'incontinenza urinaria
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
AU2001286557A1 (en) * 2000-08-23 2002-03-04 Merck Frosst Canada And Co. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria

Also Published As

Publication number Publication date
KR20050005410A (ko) 2005-01-13
WO2003070233A1 (en) 2003-08-28
EP1476146A1 (en) 2004-11-17
US20030191172A1 (en) 2003-10-09
CA2475374A1 (en) 2003-08-28
BR0307772A (pt) 2004-12-07
MXPA04008037A (es) 2004-11-26
JP2005526040A (ja) 2005-09-02
AU2003211078A1 (en) 2003-09-09
ZA200406148B (en) 2006-05-31
CN1633283A (zh) 2005-06-29

Similar Documents

Publication Publication Date Title
PL372395A1 (en) Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
EP1549614A4 (en) VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
NO20054369D0 (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
AU2003303128A8 (en) Inhibitors and methods of use thereof
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson&#39;s disease
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
HUS2200036I1 (hu) Dihidroimidazolonok alkalmazása kutyák kezelésére
SI1432701T1 (sl) Uporaba heterociklicnih spojin pri zdravljenju bolezni urinarnega trakta
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
IL158050A0 (en) Use of selective cox-2 inhibitors for the treatment of urinary incontinence
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
PL375631A1 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
GB0207411D0 (en) Azole compounds and their therapeutic use
SI1197485T1 (en) Cyclobuten-dione derivatives for use in the treatment of artherosclerosis
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
HUP0303342A3 (en) Carbamate compounds for use in preventing and treating psychotic disorders
ZA200605217B (en) Steel desulphurating agent and use thereof in the desulphuration of steel
AU2003244132A8 (en) Method of examining allergic disaese and drug for treating the same
AU2003286068A1 (en) Process for the treatment of pig manure and the use thereof
IL162776A0 (en) 2&#39;-Halo-3&#39;,5&#39;-dialkoxyphen-1&#39;-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
AU2003265281A8 (en) Methods and compositions for the enhancement of wound healing
AU2003294697A8 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)